Application of Lactobacillus fermentum LF028 in producing γ-aminobutyric acid and in preparing products for improving sleep and relieving anxiety
By optimizing the culture medium and preparation process of Lactobacillus fermentation LF028, it improves its γ-aminobutyric acid production ability and bacteria powder activity, and solves the problem of low γ-aminobutyric acid production ability of Lactobacillus, providing no side effects to improve sleep and Foods and health care products to relieve anxiety.
Patent Information
- Application Number
- CN202310060720.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-01-15
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-01-15
AI Technical Summary
In the prior art, the ability of Lactobacillus to produce γ-aminobutyric acid is generally low, resulting in dependence and drug resistance problems in insomnia and anxiety treatment, and the existing drugs have greater side effects.
By optimizing the culture medium composition of Lactobacillus fermentation, especially increasing the concentration of zinc sulfate, it significantly improves its ability to produce γ-aminobutyric acid, and improves the activity of probiotics during shelf life by improving the preparation process of bacterial powder, and is used to prepare and improve the preparation of bacterial powder. Fermented supernatant or probiotic powder for sleep and anxiety relief.
Significantly improves the γ-aminobutyric acid production of L.F028 in Lactobacillus fermentation, provides food and health products that improve sleep and relieve anxiety without side effects, and the bacteria powder remains highly active during the shelf life, suitable for a variety of Products.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of microbial engineering and relates to an application of lactobacillus, specifically to the application of fermented lactobacillus LF028 in producing gamma-aminobutyric acid and in preparing products for improving sleep and relieving anxiety. Background Art
[0002] Due to the increase in life pressure and the influence of various diseases, insomnia has become a serious health problem and has plagued people for a long time. About 10% to 15% of people worldwide suffer from insomnia, and about 25% to 35% of people experience short-term or occasional insomnia. The results of China's chronic disease and risk factor monitoring in 2007 showed that 35.7% of Chinese residents aged 15 to 69 had poor sleep quality; in 2017, Cao XL et al. used a random effects model to find that the combined time point prevalence of insomnia in the general Chinese population with a total sample size of 115,988 was 15.0%, which was significantly lower than many Western countries and similar to the survey results in other Asian countries.
[0003] Insomnia is always accompanied by anxiety, depression and other diseases. 40% of insomnia patients have one or more mental disorders, of which anxiety disorders account for 24%. There is a moderate correlation between insomnia and anxiety. Among patients with comorbid insomnia and anxiety, anxiety disorders precede insomnia in 73% of cases, and insomnia precedes anxiety in 69%. Therefore, insomnia is one of the common symptoms of anxiety attacks and the main factor in the onset of anxiety. Conversely, anxiety can also be a risk factor for chronic insomnia. Therefore, relieving anxiety is also an important means of treating insomnia.
[0004] Since drugs for insomnia and anxiety have the characteristics of fast and effective effects, drug therapy is still the most widely used in the clinical treatment of insomnia and anxiety. The more commonly used drugs for insomnia are benzodiazepines. Benzodiazepines and non-benzodiazepines Drugs; Commonly used anti-anxiety drugs in clinical practice are mainly divided into the following categories: benzodiazepines, tricyclic antidepressants, monoamine oxidase inhibitors and monoamine oxidase-reversible inhibitors, selective 5-9-tryptamine reuptake inhibitors, buspirone, etc. However, the sleeping pills or anxiety-relieving drugs currently used have side effects to varying degrees. Long-term use will cause dependence and tolerance in patients, and withdrawal reactions may occur once use is stopped.
[0005] γ-aminobutyric acid (GABA) is an inhibitory neurotransmitter that can calm the nerves and improve sleep in the human body. In recent years, some studies have shown that lactobacilli that can produce γ-aminobutyric acid and their fermentation products can play a good role in improving sleep, and this method is non-addictive or drug-resistant and has no side effects. However, the reported ability of lactobacilli to produce γ-aminobutyric acid is generally low. Summary of the invention
[0006] The technical problem to be solved by the present invention is to provide an application of Lactobacillus fermentum LF028 in producing γ-aminobutyric acid, and to improve the ability of Lactobacillus fermentum LF028 to produce γ-aminobutyric acid by optimizing the culture medium components;
[0007] Another object of the present invention is to provide an application of fermented Lactobacillus LF028 in the preparation of a fermented supernatant or probiotic powder having the effect of improving sleep and / or relieving anxiety, and by improving the powder preparation process, the activity of the probiotics in the powder during the shelf life can be improved, thereby laying a foundation for better application of fermented Lactobacillus LF028 in the preparation of related products;
[0008] The third purpose of the present invention is to provide an application of Lactobacillus fermentum LF028 in the preparation of fermented foods with sleep-improving effects, further broaden the application scope of Lactobacillus fermentum LF028, and provide healthy, safe and effective foods for insomnia patients.
[0009] In order to achieve the above object, the technical solution adopted by the present invention is:
[0010] The invention provides application of fermented lactobacillus LF028 in producing gamma-aminobutyric acid. In the application, the concentration of zinc sulfate in the fermentation medium of fermented lactobacillus LF028 is 0.01%-0.05%.
[0011] Among them, the fermented Lactobacillus LF028 was isolated and screened from the farmer's sour soup in Guiyang City, Guizhou Province. Its Latin name is Lactobacillusfermentum. The strain was preserved in the General Microbiology Center of China National Microbiological Culture Collection Administration on July 6, 2021. Its preservation number is CGMCC No. 22833, and the address of the preservation unit is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0012] The present invention also provides the use of fermented Lactobacillus LF028 in preparing a fermentation supernatant or probiotic powder having the effects of improving sleep and / or relieving anxiety. Since in practical applications, bacterial suspensions have the disadvantages of being difficult to store and transport, the present invention does not describe the use of bacterial suspensions.
[0013] As a limitation to the above application, the probiotic powder includes pure probiotic powder of fermented Lactobacillus LF028 and compound probiotic powder containing fermented Lactobacillus LF028.
[0014] As a further limitation of the above application, the method for preparing the probiotic powder comprises the following steps performed in sequence:
[0015] S1. The fermentation broth of Lactobacillus fermentum LF028 was centrifuged to obtain bacterial sludge;
[0016] S2. The bacterial sludge and the protective agent A are mixed to obtain a mixture C, and the mixture C is mixed with the protective agent B to obtain a mixture D;
[0017] S3. Dropping the mixture D into the setting liquid to form crystal beads, and freeze-drying to obtain the probiotic powder.
[0018] As a limitation of the above-mentioned method for preparing probiotic powder, the protective agent A is a 10% skim milk solution;
[0019] Protective agent B is prepared by compounding 0.4% sodium alginate, 10% trehalose, 5% maltodextrin, 6% sucrose, 0.5% vitamin C and 0.2% polyvinylpyrrolidone;
[0020] The setting liquid is 20% calcium chloride solution.
[0021] As another limitation of the above application, the viable bacteria count of the bacterial powder is 3×10 10 ~6×10 11 CFU / g.
[0022] The present invention also provides application of Lactobacillus fermentum LF028 in preparing fermented food with sleep-improving effect.
[0023] Due to the adoption of the above technical solution, the present invention has the following technical advances compared with the prior art:
[0024] ① In the application of the fermented Lactobacillus LF028 provided by the present invention in producing γ-aminobutyric acid, it is found that zinc sulfate has a regulating effect on the ability of the strain to produce γ-aminobutyric acid. When the fermented Lactobacillus LF028 seed liquid is inoculated with a 3% inoculum amount in a fermentation medium with a zinc sulfate concentration of 0.05%, and the fermentation liquid is statically cultured at 37°C for 18 hours, the content of γ-aminobutyric acid in the fermentation liquid is 387 mg / L. The appropriate concentration of zinc sulfate can significantly improve the ability of the fermented Lactobacillus LF028 to produce γ-aminobutyric acid;
[0025] ② The present invention also found that fermented Lactobacillus LF028 has a good effect of improving sleep and relieving anxiety, and the fermentation supernatant or probiotic powder obtained by the bacteria can be further used to prepare food, health food, dietary supplement or medicine with the effect of improving sleep and (or) relieving anxiety; the present invention also improves the preparation process of the bacterial powder, so that the prepared bacterial powder can better maintain the bacterial activity during the shelf life, which lays a foundation for the further application of the bacteria;
[0026] ③ The fermented dairy products, fermented bean products, fermented fruit and vegetable products and fermented cereal products prepared by fermented Lactobacillus LF028 of the present invention have a good effect of improving sleep, among which the fermented dairy product group has the best effect, and the effective rate of improving sleep is 96.7%;
[0027] ④ Compared with conventional drugs on the market that improve sleep or relieve anxiety, the product provided by the present invention has no toxic side effects and will not cause dependence or drug resistance.
[0028] In summary, the present invention provides the application of Lactobacillus fermentum LF028 in producing γ-aminobutyric acid. By selecting the zinc sulfate concentration in the culture medium, the ability of Lactobacillus fermentum LF028 to produce γ-aminobutyric acid can be significantly improved. The present invention also finds that Lactobacillus fermentum LF028 has good effects of improving sleep and relieving anxiety, and the bacteria can be used to prepare foods, health foods, dietary supplements or medicines that improve sleep and / or relieve anxiety. At the same time, the present invention can improve the activity of probiotics in the bacterial powder during the shelf life by improving the bacterial powder preparation process, laying a foundation for better application of Lactobacillus fermentum LF028 to prepare related products.
[0029] The fermented Lactobacillus LF028 provided by the present invention can be used to produce γ-aminobutyric acid and prepare probiotic products for improving sleep and relieving anxiety. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 This is a TIC graph of the fermentation broth of Lactobacillus fermentum LF028 in Example 1 of the present invention under UHPLC-QE-MS positive ion mode;
[0031] Figure 2 This is a TIC graph of the fermentation broth of Lactobacillus fermentum LF028 in Example 1 of the present invention under the negative ion mode of UHPLC-QE-MS;
[0032] Figure 3 This is a TIC graph of the blank control group in Example 1 of the present invention under the UHPLC-QE-MS positive ion mode;
[0033] Figure 4This is a TIC graph of the blank control group in Example 1 of the present invention under the UHPLC-QE-MS negative ion mode;
[0034] Figure 5 This is a secondary mass spectrum of γ-aminobutyric acid in the fermentation broth of Lactobacillus fermentum LF028 in Example 1 of the present invention;
[0035] Figure 6 The secondary mass spectrum of pentahydroxytryptophan in the fermentation broth of Lactobacillus fermentum LF028 in Example 1 of the present invention;
[0036] Figure 7 This is a secondary mass spectrum of melatonin in the fermentation broth of Lactobacillus fermentum LF028 in Example 1 of the present invention;
[0037] Figure 8 HPLC-MS spectrum of the fermentation liquid of Lactobacillus fermentum LF028 in Example 1 of the present invention;
[0038] Fig. 9 This is a statistical graph of the number of live bacteria of the probiotic powder of Lactobacillus fermentum LF028 in Example 2 of the present invention;
[0039] Fig.10 This is a statistical graph of the activity time of mice in the open field test in Example 2 of the present invention;
[0040] Fig.11 This is a statistical graph of the activity frequency of mice in the open field test in Example 2 of the present invention;
[0041] Fig.12 This is a statistical graph of the time mice stayed in the open arms in Example 2 of the present invention;
[0042] Fig.13 This is a statistical graph of the number of times mice entered the open arms in Example 2 of the present invention;
[0043] Fig.14 This is a statistical graph of the immobility time of mice in different groups in Example 2 of the present invention;
[0044] Fig.15 This is a statistical chart of the Pittsburgh Sleep Quality Index (PSQI) questionnaire results in Example 8 of the present invention. DETAILED DESCRIPTION
[0045] The present invention is further described in detail below by specific examples. It should be understood that the described examples are only used to explain the present invention, and are not intended to limit the present invention.
[0046] Unless otherwise specified, the materials and reagents used in the examples of the present invention can be obtained from commercial sources. Experimental methods without specific conditions in the examples are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0047] Example 1 Application of Lactobacillus fermentum LF028 in producing γ-aminobutyric acid
[0048] In this example, the active ingredients contained in the fermentation broth of Lactobacillus fermentum LF028 were preliminarily determined by performing non-target metabolomics detection on the fermentation broth of Lactobacillus fermentum LF028, and then the content of the active ingredients in the fermentation broth of Lactobacillus fermentum LF028 was further determined by HPLC-MS. Finally, the effect of different culture media on the ability of Lactobacillus fermentum LF028 to produce γ-aminobutyric acid was investigated.
[0049] (1) Non-target metabolomics detection of Lactobacillus fermentum LF028 fermentation broth
[0050] Metabolomics is a research concept for comprehensive analysis of metabolites. Through the correlation between metabolite analysis objects, metabolites are ranked in importance, and differences between different samples and key marker compounds that affect classification are found, so as to explore the potential rules between analysis objects and metabolites. Non-target metabolomics is committed to analyzing all small molecule chemicals that can be detected in research samples, which makes the requirements for instruments higher and the data analysis more rigorous. However, due to the comprehensiveness of the measurement, it is helpful for the analysis of unfocused or undiscovered compounds, making non-target metabolomics more general and developing more rapidly. In this example, non-target metabolomics detection was performed on the fermentation broth of Lactobacillus fermentum LF028 based on UHPLC-QE-MS. This part of the experiment was assisted by Shanghai Baiqu Biomedical Technology Co., Ltd. The detection process is as follows:
[0051] ①Sample preparation
[0052] Preparation of blank control group samples: In order to eliminate the influence of culture medium components on the fermentation metabolites of Lactobacillus fermentum LF028, a blank control group (denoted as CK group) was prepared in this example using MRS liquid culture medium. The MRS liquid culture medium was statically cultured at 37° C. for 18 h, which was synchronized with the inoculation of Lactobacillus fermentum LF028.
[0053] Preparation of fermentation broth samples of Lactobacillus fermentum LF028: Inoculate Lactobacillus fermentum LF028 into MRS liquid culture medium at a 3% inoculation rate, and culture at 37°C for 18 hours to obtain fermentation broth, which is recorded as LF028 group;
[0054] Among them, the pH of MRS liquid culture medium is 6.8, and its proportion table is shown in Table 1.
[0055] Table 1 MRS liquid culture medium ratio table
[0056]
[0057]
[0058] ②Sample processing
[0059] The culture medium or fermentation broth obtained in the previous step was centrifuged at 4°C and 8000 r / min for 15 min, and the supernatant was taken and recorded as CK group and LF028 group respectively. The biological replicates of each group were 2 cases.
[0060] Pipette 50 μL of sample into an EP tube, add 200 μL of extract (methanol:acetonitrile volume ratio of 1:1, containing isotope-labeled internal standard mixture), vortex mix for 30 seconds; ultrasonically treat in an ice water bath for 10 minutes; after standing at -40°C for 1 hour, centrifuge at 4°C and 12000 rpm for 15 minutes, and place the resulting supernatant in a sample injection bottle for inspection;
[0061] ③On-machine testing
[0062] The present invention uses a Vanquish (Thermo Fisher Scientific) ultra-high performance liquid chromatograph to perform chromatographic separation on the target compound through a Waters ACQUITY UPLC BEHAmide (2.1 mm×100 mm, 1.7 μm) liquid chromatography column; the liquid chromatography phase A is an aqueous phase containing 25 mmol / L ammonium acetate and 25 mmol / L ammonia water, and the phase B is acetonitrile; the sample plate temperature is 4° C., and the injection volume is 2 μL;
[0063] The Thermo Q Exactive HFX mass spectrometer used in the present invention can perform primary and secondary mass spectrometry data acquisition under the control of control software (Xcalibur, Thermo); the detailed parameters are as follows: Sheath gas flow rate: 30Arb, Aux gas flow rate: 25Arb, Capillary temperature: 350°C, Full ms resolution: 120000, MS / MS resolution: 7500, Collision energy: 10 / 30 / 60inNCE mode, Spray Voltage: 3.6 kV (positive) or -3.2 kV (negative).
[0064] ④Data processing method
[0065] The raw data were converted into mzXML format by ProteoWizard software, and then processed by a self-written R package (with XCMS as the kernel) for peak identification, peak extraction, peak alignment, and integration. Then, the data were matched with the self-built secondary mass spectrometry database of BiotreeDB (V2.1) for substance annotation, and the cutoff value of the algorithm score was set to 0.3;
[0066] ⑤Conclusion
[0067] The TIC chart of Lactobacillus fermentum LF028 fermentation broth under UHPLC-QE-MS positive ion mode (POS) is shown in Figure 1 As shown; the TIC diagram of Lactobacillus fermentum LF028 fermentation broth under UHPLC-QE-MS negative ion mode (NEG) is shown Figure 2 As shown; the TIC diagram of the blank control group culture medium under UHPLC-QE-MS positive ion mode (POS) is shown Figure 3 As shown; the TIC diagram of the blank control group culture medium under UHPLC-QE-MS negative ion mode (NEG) is shown Figure 4 shown; combined Figure 1-4 And secondary mass spectrometry database matching, material analysis and non-target metabolomics detection and analysis were performed, and it was found that the metabolites of Lactobacillus fermentum LF028 contained γ-aminobutyric acid, pentahydroxytryptophan and melatonin.
[0068] The secondary mass spectrum of γ-aminobutyric acid is shown in Figure 2. Figure 5 As shown; the secondary mass spectrum of pentahydroxytryptophan is as shown Figure 6 As shown; the secondary mass spectrum of melatonin is as shown Figure 7 shown.
[0069] According to the above results, the present invention further determined the contents of the three metabolites in the fermentation broth of Lactobacillus fermentum LF028 using liquid chromatography-mass spectrometry (HPLC-MS).
[0070] (2) Determination of the content of effective components in the fermentation broth of Lactobacillus fermentum LF028
[0071] The present invention uses HPLC-MS to detect the three effective components in the fermentation broth of Lactobacillus fermentum LF028. The detection part is assisted by Qingdao Kechuang Quality Inspection Co., Ltd. The process of detecting γ-aminobutyric acid and pentahydroxytryptophan is as follows:
[0072] ①Sample processing
[0073] Inoculate Lactobacillus fermentum LF028 into MRS liquid culture medium at a 3% inoculation rate, and culture at 37°C for 18 hours to obtain fermentation liquid;
[0074] Take 5 mL of the fermentation broth sample, extract it with pure water ultrasonically, add 70% methanol to dilute and precipitate the protein, centrifuge, take the supernatant and filter it through a 0.22 μm filter membrane, put it into a sample injection bottle for HPLC-MS analysis.
[0075] ②On-machine testing
[0076] The present invention uses a Thermo high performance liquid chromatograph and uses a UPLC ACQUITY BEH Amide column (2.1 mm×100 mm, 1.7 μm) for analysis. The liquid chromatography conditions for detecting the contents of γ-aminobutyric acid and pentahydroxytryptophan are as follows:
[0077] Among them, the mobile phase A was 0.15% formic acid / water (10mmol / L ammonium formate), and the mobile phase B was 85% acetonitrile / water (10mmol / L ammonium formate); an elution gradient was used, the flow rate was 0.4mL / min, the column temperature was 40°C, and the injection volume was 2μL; the elution program is shown in Table 2.
[0078] Table 2 Elution procedure for determination of γ-aminobutyric acid and pentahydroxytryptophan content in fermentation broth of Lactobacillus fermentum LF028
[0079]
[0080] The mass spectrometry conditions for detecting the contents of γ-aminobutyric acid and pentahydroxytryptophan are as follows:
[0081] Electrospray ionization (ESI) source, positive ion mode, scanning range 50-400 m / z, detection mode PRM mode, spray voltage 3.50 kV, capillary temperature 20 ° C, each ion pair is scanned and detected according to the optimized declustering potential (DP) and collision energy (CE).
[0082] ③Data processing method
[0083] In this embodiment, the free amino acid content is calculated according to Formula 1:
[0084]
[0085] Where:
[0086] W——the content of target substance in the sample, in mg / Kg;
[0087] C——Concentration of target substance in the sample solution, in mg / L;
[0088] C0——Concentration of target substance in blank control, unit: mg / L;
[0089] V——fixed volume, unit: mL;
[0090] N——dilution multiple;
[0091] m——the sampling volume of the sample, in g
[0092] ④Conclusion
[0093] The fermentation broth of Lactobacillus fermentum LF028 was detected by HPLC-MS, and the spectrum is shown in Figure 8 As shown, it was found through calculation that the content of γ-aminobutyric acid in the fermentation broth was 222.45 mg / L; pentahydroxytryptophan was below the detection limit, and the content of pentahydroxytryptophan was not detected, among which the detection limit of pentahydroxytryptophan was 10.00 mg / L;
[0094] The present invention also measured the melatonin content in the fermentation broth. The determination method was based on the method disclosed by Liu Ding (Liu Ding, Zhao Daqiu, Lu Chunliang, et al. Detection of melatonin content in peony by high performance liquid chromatography-tandem mass spectrometry [J]. Molecular Plant Breeding, 2017, 15(4): 8). However, the melatonin content was below the detection limit and the actual content of melatonin was not detected. The detection limit of melatonin was 5.00 μg / L.
[0095] (3) Effect of zinc sulfate in culture medium on the ability of Lactobacillus fermentum LF028 to produce γ-aminobutyric acid
[0096] In order to enhance the ability of fermented Lactobacillus LF028 to produce γ-aminobutyric acid, this example also investigates the effect of the zinc sulfate concentration in the culture medium on the ability of fermented Lactobacillus LF028 to produce γ-aminobutyric acid, and the specific method is as follows:
[0097] The fermented Lactobacillus LF028 was activated by using MRS liquid culture medium, and the activated Lactobacillus LF028 seed liquid was inoculated into the following five culture media A, B, C, D, and E at a 3% inoculation rate, and the five fermented liquids A, B, C, D, and E were prepared in sequence after being statically cultured at 37° C. for 18 h. The gamma-aminobutyric acid in the four fermented liquids was detected and the content was calculated according to the method described in part (2) of this embodiment;
[0098] Among them, the MRS liquid culture medium ratio table is shown in Table 1 above;
[0099] The pH of medium A was adjusted to 6.8-7.0, and its proportions are shown in Table 3;
[0100] Medium B is medium A with 0.01% zinc sulfate added, and the other components and contents remain unchanged;
[0101] Medium C is medium A with 0.05% zinc sulfate added, and the other components and contents remain unchanged;
[0102] Medium D is medium A with 0.06% zinc sulfate added, and the other components and contents remain unchanged;
[0103] Medium E is medium A with 0.07% zinc sulfate added, and the other components and contents remain unchanged;
[0104] The statistical table of γ-aminobutyric acid content in 5 fermentation broths is shown in Table 4.
[0105] Table 3 A culture medium ratio table
[0106]
[0107] Table 4 Statistical table of γ-aminobutyric acid content in 5 fermentation broths
[0108] Fermentation broth name A fermentation liquid B Fermentation Broth C fermentation broth D Fermentation broth E fermentation liquid γ-aminobutyric acid (mg / L) 231 316 387 364 218
[0109] As shown in Table 4, compared with the fermentation broth using A culture medium, the γ-aminobutyric acid content of the fermentation broth obtained by adding an appropriate amount of zinc sulfate to the B culture medium is significantly increased. When the zinc sulfate concentration in the culture medium reaches 0.05%, the yield of γ-aminobutyric acid reaches 387 mg / L. As the zinc sulfate concentration increases to 0.07%, the yield of γ-aminobutyric acid decreases to 218 mg / L. From the above data, it can be seen that within the experimental range of the present invention, zinc sulfate has a regulatory effect on the ability of fermentation lactobacillus LF028 to produce γ-aminobutyric acid. When the zinc sulfate concentration is in the range of 0 to 0.05%, the ability of fermentation lactobacillus LF028 to produce γ-aminobutyric acid gradually increases with the increase of zinc sulfate concentration; when the zinc sulfate concentration exceeds 0.05%, the ability of fermentation lactobacillus LF028 to produce γ-aminobutyric acid is inhibited; when the zinc sulfate concentration is 0.07%, the yield of γ-aminobutyric acid is reduced by 43.7% compared with the yield of γ-aminobutyric acid when the zinc sulfate concentration is 0.05%.
[0110] Lactobacillus fermentum LF028 catalyzes the decarboxylation reaction of substrate glutamic acid (Glu) or glutamate by glutamic acid decarboxylase (GAD) to generate γ-aminobutyric acid. Zinc sulfate may have a great influence on the activity of GAD in Lactobacillus fermentum LF028. Under certain concentration conditions, it can promote the activity of GAD and thus increase the production of GABA. When the concentration of zinc sulfate increases to a certain level, it inhibits the activity of GAD and thus reduces the production of γ-aminobutyric acid.
[0111] Example 2: Pure probiotic powder of Lactobacillus fermentum LF028
[0112] This example provides a preparation method of pure probiotic powder of Lactobacillus fermentum LF028, a stability study of pure probiotic powder of Lactobacillus fermentum LF028, and also investigates the effect of pure probiotic powder of Lactobacillus fermentum LF028 on sleep and anxiety symptoms.
[0113] (1) Preparation method of pure probiotic powder of Lactobacillus fermentum LF028
[0114] The method for preparing pure probiotic powder of Lactobacillus fermentum LF028 comprises the following steps performed in sequence:
[0115] S1. Take out Lactobacillus fermentum LF028 from the cryopreservation tube, inoculate it into MRS liquid culture medium at 3% inoculation amount, culture it at 37°C, keep it still, seal it, and culture it for 20h to obtain seed liquid;
[0116] The cultured activated seed liquid was inoculated into a fermentation tank at a 3% inoculation rate, and cultured in a fermentation liquid medium containing M15 at 37°C and 30rpm until the end of the logarithmic phase to obtain a fermentation liquid;
[0117] The fermentation liquid was centrifuged at 4°C and 8000 r / min for 15 min to obtain fermentation supernatant and bacterial sludge;
[0118] Among them, the pH of MRS liquid culture medium is 6.8-7.0, and its proportion table is shown in Table 5;
[0119] The pH of the fermentation liquid medium containing M15 is 6.8-7.0, and its proportion table is shown in Table 6, wherein the concentration of zinc sulfate is 0.05%;
[0120] Table 5 MRS liquid culture medium ratio table
[0121]
[0122]
[0123] Table 6 Proportion of fermentation liquid medium containing M15
[0124]
[0125] S2. The fermented Lactobacillus LF028 sludge was mixed with the protective agent A at a ratio of 1:1 at 4°C to form a mixture C, and the mixture C was then mixed with the protective agent B at a ratio of 1:1 at 4°C to form a mixture D;
[0126] Wherein, protective agent A is 10% skim milk;
[0127] Protective agent B is prepared by compounding 0.4% sodium alginate, 10% trehalose, 5% maltodextrin, 6% sucrose, 0.5% vitamin C and 0.2% polyvinylpyrrolidone;
[0128] S3. The mixture D is gradually dripped into a setting liquid made of 20% calcium chloride in an ice water bath by a dripping method to form crystal beads with a diameter of 2 mm to 4 mm. After the crystal beads are fixed in the setting liquid for half an hour, they are removed from the liquid control and placed in a pre-cooled freeze dryer. After pre-freezing for 3 hours, freeze drying is performed with a cold trap temperature of -50°C. The freeze drying is performed for 46 to 50 hours to obtain freeze-dried powder, which is the pure probiotic powder of Lactobacillus fermentum LF028, recorded as sample α.
[0129] (2) Study on the storage stability of pure probiotic powder of Lactobacillus fermentum LF028
[0130] The pure probiotic powder of Lactobacillus fermentum LF028 prepared in this embodiment adopts a double-layer embedding process, using a colloid formed by sodium alginate and calcium chloride, and then freeze-drying to form a protective layer. In order to investigate the storage stability of the pure probiotic powder of Lactobacillus fermentum LF028 prepared in this embodiment, the following experiments were conducted:
[0131] First, a control sample was prepared according to the conventional process for preparing probiotic powder in the prior art. The specific preparation method of the control sample is as follows:
[0132] Take the fermented Lactobacillus LF028 sludge prepared in step S1 of this example, and mix it with the protective agent E at 4° C. in a ratio of 1:2 to form a mixture F;
[0133] Wherein the protective agent E is a conventional freeze-drying protective agent in the prior art, specifically: 10% skim milk, 10% trehalose, 5% maltodextrin, 6% sucrose, vitamin C and 0.2% polyvinylpyrrolidone;
[0134] The mixture F was immediately placed in a pre-cooled freeze dryer, and freeze-dried after pre-freezing for 3 hours. The cold trap temperature was -50°C. The freeze-dried powder was obtained by freeze-drying for 46 to 50 hours. The obtained freeze-dried powder was the control sample, recorded as control sample β.
[0135] Sample α and control sample β were collected for viable bacteria count. The viable bacteria count of the bacterial powder was 3.0×10 11 ~6.0×10 11 The requirements are met within the CFU / g range.
[0136] According to the T / CNFIA 001 General Guidelines for Food Shelf Life, a 24-month stability test tracking study was conducted on sample α and control sample β at 25°C. The tracking results are as follows: Fig. 9 shown.
[0137] Depend on Fig. 9It can be seen that: under the condition of 25°C, the two freeze-dried powders of fermented Lactobacillus LF028 were studied for the stability of the number of live bacteria. The sample α decayed slowly, and the survival rate was 63.13% after 24 months; the control sample β decayed quickly, and the survival rate was only 39.52% after 24 months. The experimental results show that the preparation process of the probiotic powder of the present invention has a good protective effect on the live bacteria of fermented Lactobacillus LF028 after freeze-drying.
[0138] (3) Effect of pure probiotic powder of Lactobacillus fermentum LF028 on sleep in mice
[0139] This example also investigates the effect of pure probiotic powder of Lactobacillus fermentum LF028 (sample α) on the sleep of mice. The specific experimental method refers to the efficacy test method for improving sleep recorded in the "Health Food Function Test and Evaluation Method (2022 Edition)" and the "Technical Guidelines for Health Food Function Test and Evaluation" and is adaptively improved, specifically including the following contents:
[0140] Sixty healthy male Kunming white mice weighing 20±2g were selected. After being acclimated to the environment for 7 days, the model group and the treatment group were intraperitoneally injected with 400mg / kg para-chlorophenylalanine (PCPA) suspension at a fixed time every day for 2 consecutive days. The PCPA suspension was prepared by adding water to powder to make 30mg / mL. The control group was injected with an equal volume of normal saline. The status of each group was observed after 2 days. Except for the control group, the mice showed circadian disorders and mutual attacks, indicating that the insomnia model was successfully established.
[0141] The experimental mice were randomly divided into six groups, with 10 mice in each group, namely the control group, the model group, the positive drug group, the low-dose group (the number of viable Lactobacillus fermentum LF028 was 3.0×10 10 CFU / g BW), medium-dose group (live count of Lactobacillus fermentum LF028 1.5×10 11 CFU / g BW), high-dose group (live count of Lactobacillus fermentum LF028 3.0×10 11 CFU / g BW), of which the high-dose group was 10 times the recommended dose for humans; after 2 days of modeling, each group was given medication, the control group and the model group were gavaged with normal saline for 15 consecutive days; the positive control group was gavaged with estazolam (0.1 mg / kg BW) for 15 consecutive days; the low-dose group, medium-dose group and high-dose group were gavaged for 15 consecutive days, and the dosage was calculated based on the animal and human dosage.
[0142] Before and after modeling and 30 min after the last administration, the mice were placed in the autonomic activity instrument according to groups to adapt to the environment for 3 min, and the number of activities and standing times of the mice were measured within 5 min. One hour after the last administration, 45 mg / kg of sodium pentobarbital was injected intraperitoneally according to the weight of the mice, and the sleep latency and sleep time of the mice were recorded. The mice were required to keep quiet during the experiment.
[0143] SPSS22.0 was used to process the data, and one-way analysis of variance was used between groups. P<0.05 indicated a significant difference, and P<0.01 indicated a very significant difference. The statistical table of the autonomous activities of mice in different groups during the experimental period is shown in Table 7, and the statistical table of the sleep latency and sleep time of mice in different groups during the experimental period is shown in Table 8.
[0144] Table 7 Statistics of spontaneous activities of mice in different groups during the experimental period
[0145]
[0146]
[0147] Note: Compared with the same group of mice before modeling: *P<0.05, **P<0.01; compared with the same group of mice after modeling: #P<0.05, ##P<0.01.
[0148] As shown in Table 7, the activity of mice in the control group was normal before and after the experiment, and there was no fluctuation. After modeling, compared with the same group before modeling, the number of activities and standing times of insomnia mice in all groups except the control group showed significant differences (P<0.01). After drug administration, there was no significant difference in the number of activities and standing times of insomnia mice in the model group compared with that after modeling; there was a significant difference in the number of activities and standing times of insomnia mice in the low-dose group compared with that after modeling (P<0.05); there was a significant difference in the number of activities and standing times of insomnia mice in the positive drug group, the medium-dose group and the high-dose group compared with the same group after modeling (P<0.01).
[0149] Table 8 Statistics of sleep latency and sleep time of mice in different groups during the experimental period
[0150] Group Sleep latency (min) Sleep time (min) Control group 4.38±0.61 42.63±3.09 Model Group <![CDATA[10.53±1.48 ** ]]> <![CDATA[19.25±4.75 ** ]]> Positive drug group <![CDATA[3.27±0.26 ## ]]> <![CDATA[53.08±2.64 ## ]]> Low dose group <![CDATA[7.74±0.75 # ]]> <![CDATA[28.81±3.06 # ]]> Medium dose group <![CDATA[5.31±0.52 ## ]]> <![CDATA[37.49±2.95 ## ]]> High dose group <![CDATA[4.29±0.59 ## ]]> <![CDATA[45.08±3.17 ## ]]>
[0151] Note: Compared with the control group: *P<0.05, **P<0.01; Compared with the model group: #P<0.05, ##P<0.01
[0152] From the experimental results in Table 8, we can see that compared with the control group, the sleep latency of mice in the model group increased significantly (P<0.01), and the sleep time decreased significantly (P<0.01), indicating that the model was successfully established; compared with the model group, the sleep latency of mice in the low-dose group decreased significantly (P<0.05), and the sleep time increased significantly (P<0.05); the sleep latency and sleep time of mice in the other positive drug groups, medium-dose groups and high-dose groups showed extremely significant differences (P<0.01). This shows that fermented Lactobacillus LF028 has the effect of shortening the sleep latency and prolonging the sleep time of insomnia mice.
[0153] (4) Effect of pure probiotic powder of Lactobacillus fermentum LF028 on anxiety symptoms in mice
[0154] This example investigates the effect of pure probiotic powder of Lactobacillus fermentum LF028 on anxiety symptoms in mice, and the specific method is as follows:
[0155] This experiment was conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. Forty SPF-grade healthy mice weighing 20 g ± 2.5 g were selected and fed adaptively for 1 week before the experiment began;
[0156] The mice were divided into 4 groups using random number table, with 10 mice in each group, namely control group, model group, positive control group and LF028 group. Except the control group, the other groups were subjected to chronic unpredictable animal stress (CUMS), with one stimulus applied daily, and the corresponding intervention drugs were given by gavage.
[0157] Grouping and dosage design: The control group and the model group were given 200 μL of normal saline by gavage every day; the positive drug was fluoxetine, which was dissolved in normal saline to a concentration of 1.8 mg / mL every day, and the positive control group was given fluoxetine by gavage every day at a dose of 18 mg / kg BW; the LF028 group was treated with normal saline to dissolve the pure probiotic powder of Lactobacillus fermentum LF028 (sample α) every day to a final concentration of 3.0×10 10 CFU / mL, LF028 bacterial solution was prepared, and 200 μL of the LF028 bacterial solution was given by gavage every day at 8:00-9:00 am for 28 consecutive days.
[0158] Among them, the chronic unpredictable animal stress model (CUMS) was used to construct an anxiety and depression mouse model: the mice were randomly exposed to seven different stimulation methods within 28 days (4 weeks), including: 45° tilted cage, no food or water, tail clamping, day and night reversal, strobe, restraint and wet bedding. One stimulus was randomly given every day, and the same stimulus could not be applied for 3 consecutive days to ensure that the animals could not anticipate.
[0159] After 28 days, all mice underwent behavioral tests for 4 consecutive days, including open field test, elevated plus maze test and forced swimming test.
[0160] (a) Open field test (OFT)
[0161] The experimental animals were familiarized with the operator's hands and operations for 3 minutes every day before the behavioral test. The experiment was conducted in a quiet environment. After each test, the behavior box was wiped with 75% alcohol to prevent the urine or odor of the previous mouse from affecting the next test results. The mouse behavior was collected using a high-definition camera, and the behavior video of the mouse was tracked and analyzed using behavioral software. The statistical chart of the mouse open field test activity time is shown in the figure below. Fig.10 As shown in the figure, the activity frequency statistics of mice in the open field test are as follows Fig.11 shown.
[0162] Depend on Figure 10-11 It can be seen that in the open field experiment of mice, there were significant differences between the control group and the model group in the two tests of the mice's residence time in the central area and the frequency of activities in the central area (P<0.05), indicating that the chronic unpredictable animal stress model (CUMS) of mice was successfully established; in the two tests, the positive control group and the LF028 group could reverse the effects of CUMS and increase the mice's residence time and frequency of activities in the central area. There was no significant difference between the two, but there was a significant difference compared with the model group (P<0.05).
[0163] (b) Elevated plus maze (EPM) test
[0164] EPM tests the anxiety behavior of mice. The mice were placed in the middle area where the open arms and closed arms intersect, with their heads facing one closed arm. The video was recorded synchronously with the timing for a total of 10 minutes, and the number of times the mice entered the open arms and the time they stayed in the open arms were statistically analyzed. The statistical graph of the time the mice stayed in the open arms is shown in the figure. Fig.12 The statistical graph of the number of mice entering the open arms is shown in Fig.13 shown.
[0165] Depend on Figure 12-13 It can be seen that the difference between the control group and the model group was significant in the two tests of the number of times mice entered the open arms and the time they stayed in the open arms (P<0.05). In the two tests, the positive control group and the LF028 group could reverse the effects of CUMS and increase the number of times mice entered the open and closed arms and the time they stayed in the open arms. There was no significant difference between the positive control group and the LF028 group, but there was a significant difference compared with the model group (P<0.05).
[0166] (c) Forced swim test (FST)
[0167] The mice were placed in a transparent cylindrical glass tank filled with clean water at a temperature of 23℃ to 25℃, creating an inescapable oppressive environment for the mice. They began to swim desperately in an attempt to escape. After a period of effort, the mice gave up hope of escape and showed a typical floating state, i.e., a state of behavioral despair. Each mouse was tested individually. During the test, the mouse was gently placed in the water, and the swimming behavior was recorded for 6 minutes with a camera. The video images were tracked and analyzed using behavioral software, and the immobility time of the mice in the last 4 minutes of the test was counted. The immobility time statistics of mice in different groups are shown in the following figure. Fig.14 shown.
[0168] Depend on Fig.14 It can be seen that in the model group, the immobility time of mice was significantly increased, which was significantly different from the control group, positive control group and LF028 group (P<0.05), while there was no significant difference among the control group, positive control group and LF028 group, indicating that fluoxetine and fermented Lactobacillus LF028 in the positive control group can improve the despair behavior of mice induced by CUMS.
[0169] In summary, the experimental data show that after mice consumed fermented Lactobacillus LF028 powder for a period of time, their anxiety symptoms improved, and there were significant differences compared with the model group (P<0.05).
[0170] (5) Effects of pure probiotic powder of Lactobacillus fermentum LF028 on anxiety symptoms in humans
[0171] This example investigates the effect of pure probiotic powder of Lactobacillus fermentum LF028 on anxiety symptoms in humans, and the specific method is as follows:
[0172] A total of 72 subjects of all ages were recruited for the experiment. The inclusion criteria for the subjects were: no recent use of anti-anxiety or antidepressant drugs; Hamilton Depression Scale (HAMD) score ≥ 21 points, Hamilton Anxiety Scale (HAMA) score ≥ 14 points.
[0173] This experiment uses the Hamilton Anxiety Index (HAMA) for comparative analysis. The total score of HAMA can better reflect the severity of anxiety symptoms. The total score of HAMA can be used to evaluate the severity of anxiety symptoms in patients with anxiety and depressive disorders and the effects of various drugs and psychological interventions. According to the data provided by the Chinese scale collaboration group, if the total score of HAMA exceeds 29 points, it may be severe anxiety; if it exceeds 21 points, there must be obvious anxiety; if it exceeds 14 points, there must be anxiety; if it exceeds 7 points, there may be anxiety; if it is less than 7 points, there is no anxiety symptom.
[0174] The participants consumed pure probiotic powder sample 1 of Lactobacillus fermentum LF028, with a dosage of 2 g / time, three times a day, half an hour after meals, for 2 weeks. The total HAMA scores before and after consuming the probiotic powder of Lactobacillus fermentum LF028 were calculated.
[0175] The preparation method of sample 1 is to dilute the pure probiotic powder of Lactobacillus fermentum LF028 prepared in this example (i.e., sample α) with oligofructose to a viable count of 3.5×10 10 CFU / g, that is, sample 1;
[0176] The statistical table of total HAMA scores before and after consuming the fermented Lactobacillus LF028 probiotic agent is shown in Table 9.
[0177] Table 9 HAMA total score statistics before and after consuming fermented Lactobacillus LF028 probiotics
[0178]
[0179] As shown in the table, 65 out of 72 test subjects had significant physical sensations, and their anxiety index decreased, with an overall effective rate of 90.28%. The average anxiety index (HAMA) of all test subjects before consumption was 23.06, and the average anxiety index (HAMA) after consumption was 11.35, indicating that fermented Lactobacillus LF028 can relieve anxiety symptoms and improve people's quality of life.
[0180] Embodiment 3~7 Lactobacillus fermentum LF028 compound probiotic powder
[0181] Embodiments 3 to 7 are respectively a kind of fermented Lactobacillus LF028 composite probiotic powder, and the preparation method thereof is as follows: firstly, pure probiotic powder of Lactobacillus plantarum LZ010, pure probiotic powder of Lactobacillus rhamnosus GS014, and pure probiotic powder of Bifidobacterium lactis BR001 are prepared, and the preparation method thereof is in accordance with the preparation method of pure probiotic powder of Lactobacillus fermented Lactobacillus LF028 (sample α) in embodiment 2, except that the activated strains are Lactobacillus plantarum LZ010, Lactobacillus rhamnosus GS014, and Bifidobacterium lactis BR001, respectively. 4, Bifidobacterium lactis BR001, the obtained pure probiotic powder of Lactobacillus plantarum LZ010, pure probiotic powder of Lactobacillus rhamnosus GS014 and pure probiotic powder of Bifidobacterium lactis BR001 were recorded as sample 2, sample 3 and sample 4, respectively, wherein the strains of Lactobacillus plantarum LZ010, Lactobacillus rhamnosus GS014 and Bifidobacterium lactis BR001 were all commercially available products; in addition, according to the method provided in Example 2, pure probiotic powder of Lactobacillus fermentum LF028 was prepared again, recorded as sample 5. After detection and counting, the number of viable bacteria in samples 2 to 5 was 8.0×10 11 CFU / g, 1.0×10 10 CFU / g, 3.0×1011 CFU / g and 4.0×10 11 CFU / g.
[0182] At least one of samples 2 to 4 was selected and compounded with sample 5 to prepare fermented Lactobacillus LF028 compound probiotic powder. The raw material ratio table of fermented Lactobacillus LF028 compound probiotic powder prepared in Examples 3 to 7 is shown in Table 10.
[0183] Table 10 Raw material ratios in Examples 3 to 7
[0184]
[0185]
[0186] The total viable counts of the fermented Lactobacillus LF028 composite probiotic powders prepared in Examples 3 to 7 were 6.0×10 11 CFU / g, 2.7×10 11 CFU / g, 1.2×10 11 CFU / g, 5.0×10 11 CFU / g and 3.0×10 10 CFU / g.
[0187] Example 8 Application of Lactobacillus fermentum LF028 in fermented food
[0188] This embodiment provides a method for preparing fermented food using Lactobacillus fermentum LF028 as a starter, wherein the fermented food includes fermented dairy products, fermented bean products, fermented fruit and vegetable products, and fermented cereal products. The specific preparation method is as follows.
[0189] (1) Application of Lactobacillus fermentum LF028 in fermented dairy products
[0190] When preparing the coagulated fermented dairy product, Lactobacillus fermentum LF028 follows the following steps:
[0191] S1. Weigh 10 kg of raw milk, standardize it, add 5 g of zinc sulfate and 0.8 kg of arabinose, mix well and put it in a mixing tank to obtain material 1;
[0192] S2. Material 1 was homogenized at 70°C and 20MPa for 10 min, and sterilized at 90-95°C for 5-10 min to obtain material 2;
[0193] S3. Rapidly cool material 2 to 35-39°C, add sample α at a 0.01% inoculum amount, fill, cover, and ferment at 37°C until curd is achieved. The fermentation end point is when the curd is in a good state and the pH reaches 4.2-4.5. Stop the fermentation, quickly place the material in a 2-6°C refrigerator, and ripen for 12 hours to obtain coagulated fermented milk (i.e., yogurt) prepared by using Lactobacillus LF028 as a starter, which is recorded as sample γ.
[0194] (2) Application of Lactobacillus fermentum LF028 in fermented soy products
[0195] When preparing fermented soy products, Lactobacillus fermentum LF028 follows the following steps:
[0196] S1. Take 2.3kg soy milk powder raw material, add 7.7kg purified water, 5g zinc sulfate, and 1.0kg arabinose and mix well to obtain material 4;
[0197] S2. The material 4 was homogenized at 70°C and 20MPa for 10 min, and sterilized at 90-95°C for 5-10 min to obtain material 5;
[0198] S3. The material 5 was quickly cooled to 37°C, sample α was inoculated at a rate of 0.01%, the sample was filled, covered, and fermented in a fermentation chamber at 37°C for 16 hours, and then the sample was quickly cooled to 4°C and kept for about 12 hours to obtain sour soy milk prepared with fermented Lactobacillus LF028 as a starter, which was recorded as sample δ.
[0199] (3) Application of Lactobacillus fermentum LF028 in fermented fruit and vegetable products
[0200] In this embodiment, fruits and vegetables (carrots, pears, etc.) are used as raw materials, and fermented fruit and vegetable products are prepared using Lactobacillus fermentum LF028 fermentation agent. The specific method is as follows:
[0201] S1. Take 5kg of fruit and vegetable raw materials, add 5kg of purified water, 5g of zinc sulfate, and 1.0kg of arabinose and mix well to obtain material 6;
[0202] S2. The material 6 was homogenized at 70°C and 20MPa for 10 min, and sterilized at 90-95°C for 5-10 min to obtain material 6;
[0203] S3. The material 6 was rapidly cooled to 37°C, sample α was inoculated at an inoculum rate of 0.01%, the product was filled and covered, and fermented in a fermentation chamber at 37°C for 16 hours, and then rapidly cooled to 4°C and kept for about 12 hours to obtain a fermented fruit and vegetable product prepared with Lactobacillus fermentum LF028 as a starter, which was recorded as sample ε.
[0204] (4) Application of Lactobacillus fermentum LF028 in fermented cereal products
[0205] In this embodiment, cereals (rice, millet, etc.) are used as raw materials, and fermented cereal products are prepared using Lactobacillus fermentum LF028 fermentation agent. The specific method is as follows:
[0206] S1. Take rice flour and millet flour in a mass ratio of 1:1 mixed with 1kg of cereals, add 8kg of purified water, 5g of zinc sulfate, and 1.0kg of arabinose and mix well to make porridge to obtain material 7;
[0207] S2, inoculate the pure fermentation agent of Lactobacillus fermentum LF028 into material 7, fill, cover, ferment in a 37°C fermentation room for 16 hours, quickly cool to 4°C and keep for about 12 hours to obtain fermented porridge;
[0208] S3. The material 7 was cooled to 37°C under aseptic conditions, sample α was inoculated at a rate of 0.01%, the mixture was filled and covered, and fermented in a fermentation room at 37°C for 16 hours, then rapidly cooled to 4°C and kept for about 12 hours to obtain a fermented porridge prepared with Lactobacillus fermentum LF028 as a starter, which was recorded as sample ζ.
[0209] (5) Sleep treatment experiment
[0210] In order to investigate the effect of fermented food prepared by fermentation of Lactobacillus fermentum LF028 in this example on improving sleep, a sleep treatment experiment was conducted on a population, and the specific method is as follows:
[0211] 150 subjects with sleep disorders were selected; the inclusion criteria for the subjects were: healthy persons aged 20 to 75 years with sleep disorders;
[0212] The subjects were randomly divided into a control group, a yogurt group, a sour bean milk group, a fermented fruit and vegetable product group, and a fermented cereal product group. The control group had a normal diet and consumed 200 mL of pure milk after dinner. The yogurt group, the sour bean milk group, the fermented fruit and vegetable product group, and the fermented cereal product group consumed 200 grams of sample γ, sample δ, sample ε, and sample ζ (about the amount of a bowl of porridge) at dinner every day. The subjects were revisited after 2 weeks of consumption, and the results are shown in Tables 11 and 12.
[0213] Table 11 Effects of food fermented by Lactobacillus fermentum LF028 on insomniacs
[0214] Group Number of trial servers Effective number of people Efficiency Control group 30 9 30% Yogurt group 30 29 96.7% Yogurt group 30 27 90% Fermented Fruit and Vegetable Products Group 30 26 86.7% Fermented Cereal Products Group 30 28 93.3%
[0215] From the data in Table 11, we can see that the effective rate of the control group is 30%, and the effective rates of the other test groups are all above 85%. Among them, the yogurt group has the best effect, with 29 people showing obvious effects and an effective rate of 96.7%. The fermented fruit and vegetable product group has a relatively poor effect among the four experimental groups, with 4 people showing no effect and an effective rate of 86.7%. The above experiments show that the effect of fermented food with Lactobacillus LF028 on improving sleep in insomniacs is generally good, with an effective rate of more than 85.0%, and the highest effective rate is 96.7%.
[0216] Table 12 Sleep treatment effect data of each experimental group
[0217]
[0218]
[0219] From the data in Table 12, we can see that: there was no change in the control group, while the other test groups, through the fermented food trial, increased their sleep time from about 5 hours to more than 7 hours, and their sleep quality improved, the time to fall asleep was shortened, and the phenomenon of waking up at night and having too many dreams decreased; among them, the yogurt group had the best effect, with an average sleep time of 8.5 hours, a fast sleep time, and no waking up at night and having too many dreams.
[0220] One month after the trial, the subjects in each test group were interviewed again using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. The statistical results are as follows: Fig.15 shown.
[0221] The Pittsburgh Sleep Quality Index (PSQI) reflects the sleep quality, sleep onset time, sleep duration, sleep efficiency, sleep disorders, hypnotic drugs, daytime dysfunction and other indicators in the past month.
[0222] Rating scale: 0-5 points: very good sleep quality; 5-10 points: fair sleep quality; 11-15 points: average sleep quality; 16-21 points: very poor sleep quality.
[0223] Depend on Fig.15 It can be seen that the PSQI index of each group of subjects before consuming the samples was high, above 15; one month after consuming the samples, except for the control group, the PSQI index of the other groups of subjects decreased, among which the PSQI index of the yogurt group decreased by 83.07%, the PSQI index of the sour soy milk group decreased by 76.27%, the PSQI index of the fermented fruit and vegetable group decreased by 71.42%, and the PSQI index of the fermented grain group decreased by 82.38. It can be seen that the yogurt group had the best effect, and the four experimental groups can play a good role in people with insomnia.
[0224] In summary, foods fermented by Lactobacillus fermentum LF028 can effectively improve the sleep quality of people with insomnia, shorten the time to fall asleep, reduce the phenomenon of waking up at night and having many dreams, and lower the PSQI index, and have a good effect in improving sleep.
[0225] In view of the fact that fermented Lactobacillus LF028 has the function of improving sleep, the fermentation supernatant and probiotic powder of fermented Lactobacillus LF028 can be used as raw materials for food, health food, dietary supplements or medicines, and further used to prepare health food, dietary supplements or medicines according to the conventional application method of probiotics in the prior art.
[0226] In view of the fact that fermented Lactobacillus LF028 has the function of relieving anxiety, the fermentation supernatant and probiotic powder of fermented Lactobacillus LF028 can be used as raw materials for food, dietary supplements or medicines, and further used to prepare food, dietary supplements or medicines according to the conventional application method of probiotics in the prior art.
Claims
1. Application of Lactobacillus fermentum LF028 producing γ-aminobutyric acid in the preparation of probiotic powder with the effects of improving sleep and / or relieving anxiety; The preparation method of the probiotic powder comprises the following steps performed in sequence: S1. The fermentation broth of Lactobacillus fermentum LF028 was centrifuged to obtain bacterial sludge; S2. The bacterial sludge and the protective agent A are mixed to obtain a mixture C, and the mixture C is mixed with the protective agent B to obtain a mixture D; S3. dropping the mixture D into the setting liquid to form crystal beads, and freeze-drying to obtain the probiotic powder; The protective agent A is a 10% skim milk solution; Protective agent B is compounded by 0.4% sodium alginate, 10% trehalose, 5% maltodextrin, 6% sucrose, 0.5% vitamin C and 0.2% polyvinylpyrrolidone; The setting liquid is 20% calcium chloride solution; The concentration of zinc sulfate in the fermentation medium of the fermented Lactobacillus LF028 is 0.01% to 0.05%; The components of the fermentation medium except zinc sulfate include, by weight: 25 parts of glucose, 6 parts of yeast extract powder, 10 parts of peptone, 5 parts of beef extract powder, 5 parts of tryptone, 5 parts of anhydrous sodium acetate, 2 parts of diammonium hydrogen citrate, 5 parts of yeast extract, 0.05 parts of manganese sulfate, 0.01 parts of magnesium sulfate, 2 parts of dipotassium hydrogen phosphate, 0.5 parts of L-cysteine hydrochloride and 1 part of Tween 80.
2. The use according to claim 1, characterized in that: The probiotic powder includes pure probiotic powder of fermented Lactobacillus LF028 and compound probiotic powder containing fermented Lactobacillus LF028.
3. The use according to claim 1 or 2, characterized in that: The number of viable bacteria in the probiotic powder is 3×10 10 ~6×10 11 CFU / g.
4. Use of the probiotic powder of Lactobacillus fermentum LF028 producing γ-aminobutyric acid as claimed in claim 1 in the preparation of fermented food with sleep-improving effect.
